Industry Overview

Opioid-Induced Constipation (OIC) drug market was valued at $953.2 million in 2025 and is projected to reach $1,463.9 million by 2035, growing at a CAGR of 4.5% during the forecast period (2026-2035). The market is expanding primarily due to the increasing prevalence of chronic pain conditions and the corresponding rise in opioid prescriptions, which drives demand for effective constipation management therapies. Growing awareness among healthcare providers about the gastrointestinal side effects of long-term opioid use has further heightened the adoption of targeted OIC treatments. Innovations in drug development, including the introduction of selective peripherally acting ?-opioid receptor antagonists and advanced formulations of existing therapies, are enhancing treatment efficacy and patient adherence. Additionally, the availability of both prescribed and over-the-counter options is broadening market access and supporting uptake across diverse patient populations.

Market Dynamics

Rising Adoption of Targeted PAMORA Therapies

The global OIC drug market is witnessing a notable shift toward the adoption of peripherally acting ?-opioid receptor antagonists (PAMORAs), such as naloxegol and naldemedine, which offer targeted relief from opioid-induced constipation without compromising analgesic efficacy. Increased clinical evidence supporting their safety and effectiveness has encouraged prescribers to prefer these therapies over conventional laxatives. Market uptake is further supported by expanded labeling, simplified dosing regimens, and patient education programs. This trend reflects a growing emphasis on personalized treatment strategies within opioid care management. Consequently, PAMORAs are emerging as a key segment driving market expansion and shaping future therapeutic standards.

Expansion of Over-the-Counter (OTC) OIC Treatments

The availability of over-the-counter OIC medications is enhancing market penetration by providing easier access for patients managing mild to moderate constipation caused by opioid therapy. OTC formulations allow self-management and reduce the burden on healthcare providers, particularly for chronic pain patients who may require long-term care. Regulatory approvals facilitating safe OTC distribution, coupled with increasing patient awareness of gastrointestinal side effects, are encouraging broader adoption. Retail channel expansion and marketing initiatives further support accessibility and visibility. As a result, the OTC segment is becoming a significant contributor to overall market growth, complementing prescription-based therapies.

Market Segmentation

• Based on the product type, the market is segmented into lubiprostone, relistor, methyl naltrexone bromide, naldemedine, alvimopan, and others.
• Based on the prescription type, the market is segmented into prescribed drugs and over-the-counter drugs.

Lubiprostone: Leading Product Type Driving Market Adoption

Lubiprostone, classified under the product type segment, remains a leading therapy for opioid-induced constipation due to its established clinical efficacy and favorable safety profile. Its mechanism of activating chloride channels in the gastrointestinal tract provides targeted relief, making it a preferred option among prescribers for chronic pain patients on long-term opioid therapy. Market growth for lubiprostone is supported by increasing physician awareness and guideline recommendations highlighting its use in adult OIC management. Additionally, expanding global regulatory approvals have facilitated broader patient access across multiple regions.

Prescribed Drugs: Primary Prescription Segment Supporting Market Expansion

The prescribed drug sub-segment is a key contributor to the OIC drug market, reflecting the reliance on physician-guided therapy for effective constipation management in patients receiving opioids. Growth is primarily driven by the need for clinically monitored treatments, such as PAMORAs and lubiprostone, which require professional oversight for dosing and safety. Recent efforts to educate healthcare providers about OIC complications have further reinforced prescribing practices and increased patient uptake. Prescription-based access ensures adherence to treatment protocols, enhancing therapeutic outcomes and patient satisfaction. Consequently, the prescribed drug sub-segment continues to dominate market share and underpins overall market development.

Regional Outlook

The global OIC Drug market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America: Leading Market in the Global OIC Drug Landscape

North America holds a dominant position in the global OIC drug market, driven primarily by the high prevalence of chronic pain conditions and widespread opioid prescriptions across the region. Established healthcare infrastructure and extensive physician awareness of OIC management contribute to strong adoption of both PAMORAs and lubiprostone therapies. Recent product launches and expanded label approvals, such as for naloxegol and naldemedine, have reinforced the region’s market leadership. Key industry participants active in North America include Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc. / Salix Pharmaceuticals, and AstraZeneca PLC, reflecting both innovation and commercial scale. Regulatory support and reimbursement frameworks further underpin sustained growth, solidifying North America’s position as the largest contributor to the global OIC market.

Asia-Pacific: Fastest-Growing Region in the Global OIC Drug Market

The Asia-Pacific region is emerging as the fastest-growing market for OIC drugs, driven by rising opioid use for chronic pain, increasing healthcare awareness, and expanding access to prescription therapies. Growth is particularly notable in Japan, China, and India, where improving healthcare infrastructure and patient education programs are accelerating adoption of both prescription and over-the-counter OIC treatments. Market entry by global pharmaceutical players, including Takeda Pharmaceutical Company Ltd. and AstraZeneca PLC, is facilitating wider availability of PAMORAs and lubiprostone. Government initiatives to strengthen pain management protocols and ongoing clinical studies supporting efficacy further stimulate regional uptake. Consequently, Asia-Pacific represents a high-growth frontier, offering significant opportunities for market expansion and investment.

Market Players Outlook

The major companies operating in the global OIC Drug market include AstraZeneca PLC, Bausch Health Companies Inc., Pfizer Inc., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In May 2025, Shionogi & Co., Ltd. announced that China's regulatory authority had accepted the New Drug Application for naldemedine tosilate, a treatment for opioid-induced constipation (OIC). Naldemedine, a peripherally acting ?-opioid receptor antagonist developed by Shionogi, is already marketed in Japan, the US, Europe, and Taiwan, helping many OIC patients.

• In December 2024, Bausch Health and its Salix Pharmaceuticals, along with USPF, IFFGD, and ACPA, declared December 5, 2024, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. The day aims to raise awareness about OIC, a common but often overlooked side effect of opioid use, reduce stigma, and support affected patients through open conversations.

• In July 2024, Grünenthal acquired US-based Valinor Pharma and its product Movantik® (naloxegol) for approximately $250 million, including royalties, financed through available liquidity. Movantik® treats opioid-induced constipation in adults with chronic non-cancer pain.

• Luye Pharma's Mimeixin, a sustained-release tablet combining oxycodone and naloxone, was approved by China's NMPA on June 28, 2024, for managing severe adult pain, including cancer and non-cancer pain. Naloxone reduces opioid-induced constipation by blocking oxycodone's gut receptors.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global OIC drug market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.